- Randomized, Controlled Study is Designed to Evaluate Cognition  in Patients Who Continue Versus Discontinue Simufilam Over Six Months – - Target Enrollment is 100 Study Participants - AUSTIN, Texas , May 10, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.

Fireside Chat on Wednesday, April 28th at 2:30PM Eastern AUSTIN, Texas , April 27, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the B.

AUSTIN, Texas , April 26, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the Sachs 4 th Annual Neuroscience Innovation Forum , a virtual event held on

- 9 Month Interim Analysis of Open-label Study to be Presented at  a Major Scientific Conference in July 2021 as an Oral Presentation - - Initiation of Pivotal Phase 3 Program Remains On-track for 2 nd Half 2021 - - Initiation of Cognition Maintenance Study On-track for June 2021 - - Cash and cash

AUSTIN, Texas , March 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the year ended December 31, 2020 and provided business updates.

AUSTIN, Texas , March 09, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, today announced it has entered into a drug supply agreement with Evonik Industries AG for simufilam.

AUSTIN, Texas , March 08, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, has been invited to present at the H.C. Wainwright Global Life Sciences Conference , a virtual event being held

AUSTIN, Texas , Feb. 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, has been invited to present at the 10th Annual SVB Leerink Global Healthcare Conference .

- Two Upcoming Phase 3 Studies and a Previously Completed Phase 2 Program  Support a New Drug Application Filing for Simufilam in Alzheimer’s disease - - Agreement Reached to Use ADAS-Cog as Co-Primary Efficacy Endpoint - - Pivotal Phase 3 Program Remains On-track to be Initiated 2 nd Half 2021 -

AUSTIN, Texas , Feb. 12, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced registered direct offering of 4,081,633